Short CV/Education and training

  • 1978 – 1984
    Studied medicine at the University of Bonn, Germany

  • 1984
    Doctorate at the University of Bonn and research assistantship in clinical biochemistry at the University of Bonn

  • 1984 – 1985
    German Academic Exchange Service (DAAD) fellowship in gynaecological endocrinology to Eastern Virginia Medical School, Norfolk, USA

  • 1985
    Passed the FMGEMS, FLEX (American medical exams)

  • 1985 – 1992
    Specialist training in obstetrics/gynaecology at the University of Bonn Women's Clinic

  • 1989
    Internship in molecular biology at the European Molecular Biology Laboratory (EMBL), Heidelberg, Germany

  • 1989 – 1991
    German Research Foundation (DFG) fellowship to Mount Sinai Medical School, New York, USA; research topic: Gene variants of the oestrogen receptor in breast cancer

  • Since 1992
    C1 specialist in obstetrics and gynaecology

  • 1994 – 1997
    German Research Foundation (DFG) Habilitation (postdoctoral qualification) fellowship; topic: Molecular genetic alterations in female tumours

  • 1997
    Habilitation in the field of obstetrics and gynaecology at the University of Bonn, Germany

  • Since 1997
    Creation and direction of the Centre for Hereditary Breast and Ovarian Cancer at University of Bonn Women's Clinic (funded by Deutsche Krebshilfe (German Cancer Aid) from 1997 – 2005)

  • 1998 – 2003
    C2 assistant professor of obstetrics and gynaecology at University of Bonn Women's Clinic

  • Since 2003
    University professor and head of the Hereditary Breast and Ovarian Cancer programmes at the University of Cologne and the University of Bonn

  • Since 2003
    Deutsche Krebshilfe endowed professorship in molecular gynaecological oncology at the University of Cologne Women's Clinic

  • Since 2006
    Coordinator of the 12 centres for hereditary breast and ovarian cancer in Germany

Selected publications

  • Antoniou, A.C., Schmutzler, R.K., Chenevix-Trench, G.: Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA): RAD51 135GC modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. In: Am J Hum Genet 81, 2007. S. 1186-2000. IF 12.303.

  • Engert, S. et al.: MLPA screening in the BRCA1 gene from 1,506 German hereditary breast cancer cases: Novel deletions, frequent involvement of Exon 17, and occurrence in single early-onset-cases. In: Human Mutat 29, 2008. S. 948-958. IF 6.887.

  • Antoniou, A.C., Schmutzler, R.K.: Easton DF on behalf of CIMBA: Common breast cancer predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. In: Am J Human Genet 82, 2008. S. 937-948. IF 12.303.

  • Ramser, J. et al.: Rare missense and synonymous variants in UBE1 are associated with X-Linked infantile spinal muscular atrophy. In: Am J Hum Genetics 82, 2008. S. 188-193. IF 12.303.

  • Ahmed, S., Schmutzler, R.K., Easton, D.F.: Novel breast cancer susceptibility loci on 3p24 and 17q23.2. In: Nature Genetics 41, 2009. S. 585-590. IF 34.284.

  • Milne, R.L., Schmutzler, R.K., Easton, D.F.: Breast Cancer Association Consortium. Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. In: J Natl Cancer Inst 101, 2009. S. 1012-1018. IF 14.069.

  • Graeser, M.K. et al.: Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. In: J Clin Oncol 27, 2009. S. 5887-5892. IF 17.793.

  • Meindl, A., Schmutzler, R.K., Hanenberg, H. (contributed equally): Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. In: Nature Genetics 42, 2010. S. 410-414. IF 34.284.

  • Audeh, M.W. et al.: Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutation and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010 Jul 5 (Epub ahead of print). IF 30.758.

  • Tutt, A. et al.: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010 Jul 5 (Epub ahead of print). IF 30.758.


Selected projects

  • The Centre for Hereditary Breast and Ovarian Cancer includes a research department for molecular gynaecological oncology. Here, we explore current scientific issues of relevance to clinical practice concerning the genetic bases of, and new gene therapy strategies for, breast and ovarian cancer.

Membership in scientific bodies/juries

  • Member of the German Medical Association ethics committee, since 2010

  • Executive committee of the German Society for Obstetrics and Gynaecology (DGGG), since 2010

  • Elected member of the expert commission, German Research Foundation (DFG), since 2005

  • Spokesperson of the German Consortium for Hereditary Breast and Ovarian Cancer, since 2005

  • Member of the expert commission, Deutsche Krebshilfe (German Cancer Aid), since 2004

Contact

You can only see the contact information of the academics in the database if you are a registered user of AcademiaNet.
Please register here

Testimonials

  1. Read what our members say about AcademiaNet.

No more excuses!

  1. Please download the brochure "No more excuses" and read more about female experts in Europe, and about AcademiaNet.

Similar profiles

  1. Prof. Dr. Myriam Aouadi

    HealthObesity, Diabetes, Immunology

  2. Prof. Dr. Katrin Amunts

    HealthBrain Research

  3. Dr. Irene Agyepong

    HealthPublic Health

  4. Dr. Nicola Allen

    HealthRole of astrocytes in brain function